Kilpatrick Townsend & Stockton LLP
Crystalline and non-crystalline forms of SGLT2 inhibitors
The present invention provides amorphous forms and the crystalline complexes of SGLT2 inhibitors as a novel material, in particular in pharmaceutically acceptable form. The crystalline forms of SGLT2 inhibitor canagliflozin are designated as Forms CS1, CS2, CS3, CS4 and CS5.
ScinoPharm Taiwan, Ltd.
C A C C A
C07D A61P C07D C07D A61P
inventional inventional inventional inventional inventional
Meng-Fen Julian Paul Yung-Fa Shu-Ping
Ho Henschke Chen Chen